返回 Agenda
[Session 3] Abstract Session 1
Session Chair(s)
Naoki Furuyama, DVM, PhD
Medical Information & Communication, Japan Medical Affairs
Takeda Pharmaceutical Company Limited, Japan
Yuji Kumagai, MD, PhD
Professor, Kitasato Clinical Research Center
Kitasato University Hospital, Japan
Speaker(s)
Can we rely on automated ECG machine measurements for clinical trial decisions?
Robert Kleiman, MD
ERT, United States
Chief Medical Officer and Vice President, Global Cardiology
Heart Rate Correction When the Drug Affects Heart Rate
Georg Ferber
Statistik Georg Ferber GmbH, Switzerland
Statistical Consultant
Intensive QT investigation as standard practice in early clinical programs
Sanae Yasuda, PhD
Eisai, Japan
Executive Director, Clinical Pharmacology Science, Deep Human Biology Learning
Evaluation of a proposed novel biomarker, the JTpeak interval, for evaluation of proarrhythmic liability
Börje C. Darpö, MD, PhD
Clario, Sweden
Chief Scientific Officer, Cardiac Safety
Influence of Food on QT, J-Tpeak and Tpeak - Tend Intervals
Jorg Taubel, MD, FFPM
Richmond Pharmacology, United Kingdom
Chief Executive Officer